# A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

> **NCT02675426** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 661 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT02675426
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-17
- **Primary completion:** 2017-04-21
- **Final completion:** 2022-03-10
- **Target enrollment:** 661 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675426, "A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02675426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*